TRANSFORM-HF Mortality Comparison Index
Randomized trial outcome
Published results comparing torsemide with furosemide after hospitalization for heart failure.
TRANSFORM-HF randomized 2,859 patients hospitalized with heart failure, regardless of ejection fraction, to a torsemide or furosemide treatment strategy. The figures below are observed trial-group outcomes, not individualized predictions.
Selected 12-month outcomes
| Outcome | Torsemide | Furosemide | Effect estimate |
|---|---|---|---|
| All-cause mortality | 26.1% | 26.2% | HR 1.02 (95% CI 0.89–1.18) |
| Death or all-cause hospitalization | 47.3% | 49.3% | HR 0.92 (95% CI 0.83–1.02) |
| Total hospitalizations | 940 | 987 | Rate ratio 0.94 (95% CI 0.84–1.07) |
Clinical interpretation
TRANSFORM-HF compared post-discharge loop-diuretic strategies in a pragmatic, open-label randomized trial. Its primary mortality result was neutral; the confidence interval includes both possible benefit and possible harm.
What these results mean
- The observed mortality proportions were very similar between randomized groups.
- The primary outcome did not establish a mortality advantage for torsemide over furosemide.
- Secondary estimates also had confidence intervals that included no difference.
- Diuretic selection should be individualized to clinical response, congestion, renal function, dose, adherence, availability, and clinician judgement—not to an unvalidated mortality estimate.
Important limitation
The supplied original code included a logistic equation with coefficients described as an approximation, plus a modeled 5% torsemide adjustment. The source code did not provide a validated derivation, calibration, discrimination, or external validation for that equation. Those calculations have therefore not been retained as patient-level risk estimates.
Primary reference
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.